(secondQuint)Multicentre, Dose Finding, Ph II,CP-4055 in Comb.

 With Sorafenib - Patients With Metastatic Malignant Melanoma.

 This is a multicentre clinical study conducted in the USA and in Europe.

 It is an open label study designed to investigate objective tumor response, the time to progression (TTP) and the duration of tumor response in patients with metastatic malignant melanoma when treated with CP-4055 in combination with sorafenib (Nexavar(R)).

 The safety and tolerability of the treatment will also be assessed.

.

 Multicentre, Dose Finding, Ph II,CP-4055 in Comb.

 With Sorafenib - Patients With Metastatic Malignant Melanoma@highlight

Patients with metastatic malignant melanoma will receive CP-4055 200 mg/m2/day intravenously (IV) on Day 1-5 every four weeks and sorafenib 400 mg b.

i.

d.

 (twice daily) every day until complete response or disease worsening/progressing.

